Management Q&A: View from the Top

How Nobilis Health Will Break Out of the Healthcare Payment Mold

Managment Q&A: View from the Top
Source: George S. Mack of The Life Sciences Report   (05/25/2016)
How Nobilis Health Will Break Out of the Healthcare Payment Mold
Managing both acquisitions and internal growth at the same time is difficult for most small companies, but not for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. read more >

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016

Source: The Life Sciences Report  (05/18/2016)
With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company. read more >
Management Q&A: View from the Top

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (05/11/2016)
Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers run a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution. read more >

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Source: George S. Mack of The Life Sciences Report  (05/11/2016)
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Unmet medical needs exist all over the globe, creating a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare analyst Dennis Hulme of Edison Investment Research cites a group of Australian medtech and biotech names that investors should look at very carefully. read more >
Management Q&A: View from the Top

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (05/04/2016)
Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Executive Chairman James "Jim" Joyce of Exosome Sciences, a subsidiary of Aethlon Medical Inc., shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. read more >

Delving Deep into Immune Pharmaceuticals' Diverse Pipeline

Contributed Opinion
Source: Jason Napodano  (05/04/2016)
Delving Deep into Immune Pharmaceuticals' Diverse Pipeline
Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focusing on the treatment of immuno-inflammatory diseases and cancer. The company has several active clinical programs, led by bertilimumab, which is in Phase 2 for the treatment of inflammatory bowel disease and skin disorders. Analyst Jason Napodano digs into the company's pipeline and investment potential. read more >

Let Volatility Power Your Micro-Cap Biotechs

Source: George Mack of The Life Sciences Report  (04/27/2016)
Let Volatility Power Your Micro-Cap Biotechs
ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock—no matter how far into the depths it may have sunk—and presents his detailed growth theory on two names, plus two picks for investors to do further diligence on. read more >
Expert Investing Ideas

"HLTH reported solid revenue growth for Q1/16."

–William Sutherland, Emerging Growth Equities Ltd.


NASDAQ Biotech ARCA Pharmaceutical
Management Q&A: View from the Top

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (04/27/2016)
Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. read more >
Management Q&A: View from the Top

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse

Managment Q&A: View from the Top
Source: Special to The Life Sciences Report  (04/20/2016)
Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. read more >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer

Source: George S. Mack of The Life Sciences Report   (04/20/2016)
What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease. In this interview, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to extend the lives of thousands of men. read more >

Drug Pricing, Presidential Politics, and Three Biotechs with Promise

Source: George S. Mack of The Life Sciences Report  (04/13/2016)
Drug Pricing, Presidential Politics, and Three Biotechs with Promise
George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. read more >
Biotech Watchlist 2016